Biopharma leaders driving digital pathology united at the 2nd Translational Digital Pathology & AI Summit for exclusive, high-impact networking discussions in intimate, deep-dive sessions.
Technology and expertise were showcased to key decision-makers shaping the future of digital pathology. Attendees had the opportunity to demonstrate how their platforms can support the field by streamlining operational workflows, revealing novel insights, and uncovering more precise biomarkers — opening the door to major partnerships.
At a time when the field demanded alignment, organizations positioned themselves as leaders easing implementation, driving standardization, and boosting the adoption of digital pathology.
Why Partner?
 |
Connect directly with senior biopharma decision-makers actively seeking innovative AI, image analysis, and digital pathology solutions to advance their R&D and clinical programs |
 |
Position your technology as a critical enabler for improving diagnostic accuracy, accelerating drug development, and unlocking new biomarker and CDx opportunities |
 |
Showcase your expertise and thought leadership alongside industry pioneers, strengthening your brand and driving meaningful collaborations across biopharma and diagnostics |
Biopharma Companies Are Looking to Partner With
Official Partners Include
Want to Learn More About Partnering?
Contact Thomas Walsh, Partnerships Director at: sponsor@hansonwade.com
Who Did We Meet?
Directors, Heads, and Vice Presidents of Pathology, Translational Research, Image Analysis, Precision Medicine, Data Science, and more came together to overcome key challenges, including the lack of versatility and standardization in protocols — while working to build digitally enabled IT infrastructures that fully support digital pathology across the full workflow for better patient outcomes.
Find Out More
Explore the brochure today for more information about who's attending, what our audience is looking for, and how you can get involved before securing your spot as a trusted partner of biotech and pharma organizations driving the adoption and standardization of digital pathology.
